when were glp-1 agonists approved for weight loss Navigating the -tides: Medication-Assisted on the Forefront Could GLP-1 medications be helpful

Research and development of safe and effective anti-obesity pharmacotherapies is urgently needed considering the current obesity epidemic

For example, naltrexone-bupropion is not suitable for patients with uncontrolled hypertension [62] and phentermine is contraindicated in patients with a history of cardiovascular disease [63]

Government Initiatives and Regulatory Support Supportive Policies: Government initiatives and regulatory frameworks are crucial in driving market growth by addressing supply shortages and promoting the development of safe medications

Does GLP-1 treatment lead to muscle loss

In Turners experience, living on these products is not fun

Distinguishing characteristics are their improved safety profile and the potential for chronic use